semaglutide and gallstones GLP-1 receptor agonists gallbladder disease risk: insights into molecular mechanisms and clinical implications Semaglutide and Gallstones: Safety Tips

Physician-supervised GLP-1 weight loss programs at Youtherapy MedSpa

Trial registrations ClinicalTrials.gov identifiers: NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381, NCT01720446, NCT02207374, NCT02254291, NCT02906930, NCT02863328, NCT02607865, NCT02863419, NCT02827708, NCT02692716, NCT02849080, NCT03021187, NCT03018028, NCT03015220.

Notably, glucagon-like peptide-1 (GLP-1)-based drugs are being successfully used to control glucose levels in patients with diabetes mellitus

Helps reduce food cravings, supporting metabolic health and weight maintenance

However, the coexistence of micro and macrovascular disease is associated with the highest cardiovascular risks which highlights the importance that pharmacological treatment of type 2 diabetes mellitus provides not only glycemic control, but also cardiovascular safety